TOP2A inhibition reverses drug resistance of hepatocellular carcinoma to regorafenib.
Zongwen Wang, Qiankun Zhu, Xiaodong Li, Xiaohang Ren, Jingtao Li, Yao Zhang, Shicong Zeng, Lishan Xu, Xiaoqun Dong, Bo Zhai
Abstract
. Thus, targeting TOP2A may be a promising therapeutic strategy to alleviate resistance to regorafenib and thus improving the efficacy of HCC treatment.
Topics & Concepts
RegorafenibSorafenibHepatocellular carcinomaCancer researchMedicineDoxorubicinDrug resistanceDownregulation and upregulationGene silencingCarcinogenesisColorectal cancerCancerPharmacologyInternal medicineBiologyChemotherapyGeneBiochemistryMicrobiologyCancer therapeutics and mechanismsCancer Mechanisms and TherapyLung Cancer Treatments and Mutations